• KOL
    • Gastric Cancer
    • Mitsuru Sasako
    • Mitsuru Sasako: Influence Statistics

      Mitsuru Sasako

      Mitsuru Sasako

      Show email address

      Department of Surgery, Yodogawa Christian Hospital, Osaka, Japan. | Department of Surgery, Yodogawa Christian Hospital, 1-7-50, Kunijima, Higashiyodogawa-ku, 533-0024, Osaka, ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Mitsuru Sasako:Expert Impact

      Concepts for whichMitsuru Sasakohas direct influence:Gastric cancer,Adjuvant chemotherapy,Lymph node,Total gastrectomy,Neoadjuvant chemotherapy,Advanced gastric cancer,Bone marrow,Early gastric cancer.

      Mitsuru Sasako:KOL impact

      Concepts related to the work of other authors for whichfor which Mitsuru Sasako has influence:Gastric cancer,Lymph node,Adjuvant chemotherapy,Total gastrectomy,Endoscopic submucosal dissection,Postoperative complications,Stomach neoplasms.

      KOL Resume for Mitsuru Sasako

      Year
      2022

      Department of Surgery, Yodogawa Christian Hospital, Osaka, Japan.

      2021

      Department of Surgery, Yodogawa Christian Hospital, Osaka, Japan

      2020

      Hyogo College of Medicine, Department of Surgery, Japan.

      Yodogawa Christian Hospital, Osaka, Japan

      2019

      Division of Upper Gastrointestinal Surgery, Department of Surgery, Hyogo College of Medicine, Nishinomiya, Japan

      2018

      Department of Multidisciplinary Surgical Oncology, Hyogo College of Medicine, Nishinomiya, Japan

      2017

      Hyogo College of Medicine, Nishinomiya, Japan

      2016

      Upper GI Division, Department of Surgery, Hyogo College of Medicine, Hyogo, Japan

      2015

      Department of Surgery, Hyogo College of Medicine,Hyogo, Japan

      2014

      Department of Upper Gastrointestinal Surgery, Hyogo College of Medicine, 1-1 Mukogawa-cho, 663-8501, Nishinomiya, Hyogo, Japan

      2013

      Department of Surgery, Hyogo College of Medicine, Hyogo, Honshu 663-8501, Japan

      2012

      Department of Upper Gastrointestinal Surgery, Hyogo College of Medicine, 1-1 Mukogawa-Cho, 663-8501, Nishinomiya, Hyogo, Japan

      2011

      Hyogo College of Medicine, Nishinomiya

      Graduate School of Medical Sciences, Kumamoto University, Kumamoto

      From Teikyo University School of Medicine

      and Gastroenterology Center, International University of Health and Welfare Mita Hospital, Tokyo

      Gastric Surgery Division, National Cancer Center Hospital, Chuo-ku, Japan

      2010

      Digestive Surgery, Hyogo Medical College, Hyogo, Japan

      Upper GI Surgery Division, Department of Surgery, Hyogo College of Medicine, Hyogo

      2009

      Gastric Surgery Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, 104-0045, Tokyo, Japan

      2008

      Department of Surgical Oncology, National Cancer Center Hospital, 5‐1‐1 Tsukiji, Chuo‐ku, Tokyo 104‐0045, Japan

      From the Gastric Surgery Division, National Cancer Center Hospital, Tokyo (M.S., T.S.)

      Orthopaedic Surgery, Gastrointestinal Oncology, Gastric Surgery, and Clinical Laboratory Divisions, National Cancer Center Hospital

      Cancer Transcriptome Project, National Cancer Center Research Institute

      BioBusiness Group, Mitsui Knowledge Industry, Tokyo

      2007

      Department of Surgery, National Cancer Center Hospital, 1-1 Tsukiji 5-chome, Chuo-ku, 104-0045, Tokyo, Japan

      National Cancer Center Hospital (M.S.), the Cancer Institute Hospital (T.Y., T.N.), Nihon University School of Medicine (M.F.), University of Tokyo (Y.O.), and Tokyo Metropolitan Komagome Hospital (K.A.) — all in Tokyo

      2006

      National Cancer Center Hospital, Tokyo, Japan.

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Mitsuru Sasako is among the top experts in the world.
      Concept World rank
      gastrectomy hospital #1
      55 65 cent #1
      cáncer gástrico hacia #1
      location clinicopathological features #1
      patients damy3 #1
      longterm survival nogca #1
      10 cutoff survival #1
      lnmresults #1
      ibl curative gastrectomy #1
      egc mass screening #1
      standard techniques guidelines #1
      jcog1507 #1
      publication humans stomach #1
      leakage postoperative stenosis #1
      16 introduction #1
      dissection gastric #1
      survival distal gastrectomy #1
      lymphadenectomy european #1
      confirm modified #1
      complications pprc #1
      dissection local control #1
      jcog1002 docetaxel #1
      large difference survival #1
      society gastric #1
      scrp3 pprc #1
      fgf9 mediator #1
      birdie #1
      abscess gastrectomy #1
      complications criteria #1
      odg japan #1
      cutoff values scrp3 #1
      cardia subcardia #1
      serosal invasion difference #1
      randomized odg #1
      clinical stage ladg #1
      pancreatectomy relative risk #1
      jcog0110 study #1
      pprc damy1 #1
      nct00149266 #1
      ct34 tumors #1
      materials neoplasms tomography #1
      gastrectomy terms #1
      gastrectomy humans dissection #1
      cancerassociated fibroblasts mediator #1
      it0116 #1
      gastrectomy pancreas complications #1
      odg proportion #1
      curable gastric #1
      analyses patient population #1
      gastrectomy operation time #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Mitsuru Sasako

      KOL-Index: 20356

      BACKGROUND: Chemotherapy is the standard of care for incurable advanced gastric cancer. Whether the addition of gastrectomy to chemotherapy improves survival for patients with advanced gastric cancer with a single non-curable factor remains controversial. We aimed to investigate the superiority of gastrectomy followed by chemotherapy versus chemotherapy alone with respect to overall survival in these patients.

      METHODS: We did an open-label, randomised, phase 3 trial at 44 centres or ...

      Known for Gastrectomy Chemotherapy | Advanced Gastric | Single Noncurable Factor | 95 Patients | Phase 3
      KOL-Index: 18059

      BACKGROUND: We investigated the superiority of docetaxel plus cisplatin and S-1 compared with cisplatin and S-1 in chemotherapy-naive patients with advanced gastric cancer.

      METHODS: In this open-label, phase 3, randomised controlled trial, patients were recruited from 56 hospitals in Japan. We enrolled individuals aged 20-75 years who had unresectable or recurrent gastric cancer, had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, had received no previous ...

      Known for Advanced Gastric Cancer | S1 Cisplatin | Phase 3 | Adjuvant Chemotherapy | Aged Neoplasm
      KOL-Index: 16965

      We evaluated the significance of aberrant DNA methyltransferase 1 (DNMT1) protein expression during gastric carcinogenesis. The protein expression of DNMT1, Muc2, human gastric mucin, E-cadherin, and proliferating cell nuclear antigen was examined immunohistochemically in gastric cancers and corresponding noncancerous mucosae from 134 patients. The DNA methylation status of the CpG islands of the p16, human MutL homologue 1 (hMLH1), E-cadherin, and thrombospondin-1 (THBS-1) genes and the ...

      Known for Cpg Islands | Gastric Cancers | Protein Expression | Dna Hypermethylation | Ebv Infection
      KOL-Index: 16553

      PURPOSE: Using multiple genetic markers, including cancer stem-like cells, we evaluated the clinical significance of circulating tumor cells (CTCs) as a prognostic factor for overall survival (OS) and disease-free survival (DFS) in the peripheral blood (PB) of patients with colorectal cancer (CRC) who had undergone curative surgery.

      PATIENTS AND METHODS: In a multi-institutional study, 735 patients with CRC were assigned to a retrospective training set (n = 420) or prospective validation ...

      Known for Peripheral Blood | Clinical Significance | Colorectal Cancer | Ck Cd133 | Dukes Stage
      KOL-Index: 16386

      BackgroundGastric cancer with extensive lymph node metastasis is commonly considered unresectable, with a poor prognosis. We previously reported the results of the use of cisplatin and S-1 as preoperative chemotherapy for gastric cancer with extensive lymph node metastasis; docetaxel, cisplatin, and S-1 (DCS) have now been investigated for the same purpose.MethodsPatients received two or three 28-day cycles of DCS therapy (docetaxel at 40 mg/m2 and cisplatin at 60 mg/m2 on day 1, S-1 at ...

      Known for Preoperative Chemotherapy | Lymph Node | Gastric Cancer | Cisplatin S1 | Dcs Therapy
      KOL-Index: 14512

      BACKGROUND: Locally advanced gastric cancer with extensive regional and/or para-aortic lymph node (PAN) metastases is typically unresectable and associated with poor outcomes. This study investigated the safety and efficacy of S-1 plus cisplatin followed by extended surgery with PAN dissection for gastric cancer with extensive lymph node metastasis.

      METHODS: Patients with gastric cancer with bulky lymph node metastasis along the coeliac artery and its branches and/or PAN metastasis ...

      Known for Lymph Node | Gastric Cancer | Pan Dissection | Neoadjuvant Chemotherapy | S1 Cisplatin
      KOL-Index: 14202

      BACKGROUND: Lymph node status is a major determinant of disease recurrence after patients undergo curative resection for gastric carcinoma. A proportion of patients without lymph node metastasis develop systemic recurrences. Recent studies in a range of solid tumors have found a high incidence of micrometastases in the regional lymph nodes of patients with apparently negative lymph nodes. In patients with breast and colorectal carcinoma, the presence of micrometastases has been ...

      Known for Gastric Carcinoma | Patients Micrometastases | Lymph Nodes | Immunohistochemically Detected | Node Metastasis
      KOL-Index: 13779

      BackgroundSome patients develop recurrence after curative resection and adjuvant chemotherapy. S-1, an oral fluoropyrimidine, is one of the standard regimens in adjuvant chemotherapy, and is also used in first-line treatment for advanced/metastatic gastric cancer. It is controversial as to whether the same treatment strategy can be applied for patients who develop recurrence after adjuvant chemotherapy and those who did not receive adjuvant chemotherapy. To investigate this issue, we ...

      Known for Adjuvant Chemotherapy | Gastric Cancer | Recurrence Patients | Exploratory Analysis | Aged Neoplasm
      KOL-Index: 13746

      BackgroundsNo confirmatory randomized controlled trials (RCTs) have evaluated the efficacy of laparoscopy-assisted distal gastrectomy (LADG) compared with open distal gastrectomy (ODG). We performed an RCT to confirm that LADG is not inferior to ODG in efficacy.MethodsWe conducted a multi-institutional RCT. Eligibility criteria included histologically proven gastric adenocarcinoma in the middle or lower third of the stomach, clinical stage I tumor. Patients were preoperatively randomized ...

      Known for Ladg Odg | Surgical Outcomes | Distal Gastrectomy | Nodal Dissection | Clinical Stage
      KOL-Index: 13593

      BACKGROUND: Advanced gastric cancer can respond to S-1, an oral fluoropyrimidine. We tested S-1 as adjuvant chemotherapy in patients with curatively resected gastric cancer.

      METHODS: Patients in Japan with stage II or III gastric cancer who underwent gastrectomy with extended (D2) lymph-node dissection were randomly assigned to undergo surgery followed by adjuvant therapy with S-1 or to undergo surgery only. In the S-1 group, administration of S-1 was started within 6 weeks after surgery ...

      Known for Oral Fluoropyrimidine | Adjuvant Chemotherapy | Gastric Cancer | Surgery S1 | 1 Year
      KOL-Index: 13550

      BACKGROUND: The usefulness of preoperative oral antibiotics for the prevention of surgical site infection in elective colorectal surgery remains controversial.

      OBJECTIVE: This study aimed to investigate the effects of oral antimicrobial prophylaxis in addition to intravenous antimicrobial prophylaxis on patients with ulcerative colitis undergoing restorative proctocolectomy.

      DESIGN: This study was a randomized, nonblinded, single-center clinical trial.

      SETTING: This study was conducted ...

      Known for Surgical Site Infection | Ulcerative Colitis | Oral Antibiotics | Antimicrobial Prophylaxis | Intravenous Administration
      KOL-Index: 13328

      BACKGROUND: The incidence of adenocarcinoma of the gastric cardia has increased recently in the West. However, in Japan, most patients with gastric carcinoma have disease that is situated in the body and the distal stomach. The objectives of this study were to compare the clinicopathologic findings of patients with early gastric carcinoma (EGC) arising at the cardia and those with carcinoma in more distal parts of the stomach, then comparing the findings with those from patients with ...

      Known for Gastric Cardia | Patients Egc | Barrett Esophagus | Distal Stomach | Body Mass Bmi
      KOL-Index: 13065

      BACKGROUND: Historical data and recent studies show that standardised extended (D2) lymphadenectomy leads to better results than standardised limited (D1) lymphadenectomy. Based on these findings, the Dutch D1D2 trial, a nationwide prospectively randomised clinical trial, was undertaken to compare D2 with D1 lymphadenectomy in patients with resectable primary adenocarcinoma of the stomach. The aim of the study was to assess the effect of D2 compared with D1 surgery on disease recurrence ...

      Known for Surgical Treatment | Gastric Cancer | D1 Lymphadenectomy Patients | Curative Intent | Year Follow
      KOL-Index: 12972

      BACKGROUND: The Japanese population is rapidly aging, and the actual number of elderly patients with gastric cancer, including early cancer, has been increasing, even though the standardized incidence of gastric cancer in the population is decreasing. The optimal treatment for these patients remains a challenge to the surgeon. The aim of this retrospective analysis was to describe the results of gastrectomy and EMR for early gastric cancer in elderly patients (80 years of age and ...

      Known for Gastric Cancer | Elderly Patient | Emr Gastrectomy | Tumor Size | Treatment Early

      Key People For Gastric Cancer

      Top KOLs in the world
      #1
      Freddie Ian Bray
      cancer incidence nordic countries mortality rates
      #2
      Jacques Ferlay
      cancer incidence global burden latin america
      #3
      Ahmedin M Jemal
      united states breast cancer addis ababa
      #4
      Rebecca L Siegel
      united states colorectal cancer incidence rates
      #5
      David Forman
      gastric cancer helicobacter pylori eradication therapy
      #6
      Jaffer A Ajani
      gastric cancer esophageal adenocarcinoma preoperative chemoradiation

      Department of Surgery, Yodogawa Christian Hospital, Osaka, Japan. | Department of Surgery, Yodogawa Christian Hospital, 1-7-50, Kunijima, Higashiyodogawa-ku, 533-0024, Osaka, Japan | Department of Surgery, Yodogawa Christian Hospital, Osaka, Japan 53

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.